The company have announced that durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144] did not meet the primary endpoints of overall survival compared to standard-of-care chemotherapy in the Phase III EAGLE trial. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
04 April 2019 Suspended, The company have announced that durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144] did not meet the primary endpoints of overall survival compared to standard-of-care chemotherapy in the Phase III EAGLE trial. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance